WAM
HZNP

Wolverine Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Wolverine Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-26,100
Closed -$385K – 1517
2017
Q1 		$385K Buy
26,100
+6,500
+33% +$105K 0.01% 746
2016
Q4 		$317K Buy
+19,600
New +$355K ﹤0.01% 771

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Wolverine Asset Management's HZNP Position: Q4 2023 in Review

Wolverine Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 39,899 shares — an estimated $4.62M sold.

Wolverine Asset Management first reported a position in HZNP in Q4 2016 and held it in 15 quarters. The position peaked at $4.62M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Wolverine Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Wolverine Asset Management sold 39,899 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $4.62M.
  • Wolverine Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2016 and held it in 15 quarters.
  • Wolverine Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $4.62M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Wolverine Asset Management's 13F filing for Q4 2023, filed 1 Feb 2024.